Wisconsin Alumni Research Foundation

Wicell Research Institute, Inc.

Other

Polaris Group

Pfizer Corporation

Amgen Fremont Inc.

Cellular Dynamics International, Inc.

Tdw Group

Northwestern University

Fujifilm Cellular Dynamics, Inc.

James A Thomson

Igor I Slukvin

Maksym A Vodyanyk

Guokai Chen

Jue Zhang

Junying Yu

Zhonggang Hou

Maryna E Gumenyuk

William Leo Murphy

Michael P Schwartz

Srikumar Sengupta

Richard E Showalter

Tenneille Ludwig

Ren-He Xu

Robert Almassy

Vahe Bedian

Michael Aidan North

Xin Jiang

Dana Dan Hu-Lowe

Jianying Wang

James C Fletcher

Laura Lee Kiessling

Amanda Mack

David J Wilson

Dan Samuel Kaufman

Thomas R Lawrence

Bor-Wen Wu

Gene Ichiro Uenishi

Shelley Sims Belouski

Brendan Patrick Orner

Werner K Dahm

Michael C Krause

Dong Chen Chen

Su-Chun Zhang

Deepika Rajesh

Wayne H Keene

Timothy Joseph Kamp

Albert V Jelalian

Sirid-Aimee Kellermann

Erik J Sontheimer

Yue Ma

Charles M Sonnenschein

William C Cliff

Elena Brin

Rakhi Rajan

Karin Kristina Amundson

Shannon Marie Karlicek

Grant Raymond Wickman

Jingchuan Zhang

Nicholas E Propson

Robert M Huffaker

Wes Sisson

Wei-Jong Shia

Li-Chang Chen

Yang Lee

Ratmir Derda

Sirid Aimee Kellerman

Vivienne S Marshall

Jennifer J Swiergiel

Ronald B Campbell, Jr

Veit Bergendahl

Wei He

Yan Zhang

Yunyun Guo

Ian David Duncan

Brian McIntosh

Nicholas Seay

James W Bilbro

Harold B Jeffreys

Charles D Page

Wen-Chin Tsai

Sirid-Aimée Kellerman

John Maufort

Gene I Uenishi

Sarah Jane Dickerson

Jiaojuan He

Michael Miller

Shelly Sims Belouski

Thomas P Zwaka

Jia-Qiang He

Mark Levenstein

Alfonso Mondragon

Xue-Jun Li

Maksym Vodyanyk

Nick Seay

The present invention relates to methods for deriving human hematopoietic progenitors, primitive macrophages, and microglial cells from human pluripotent stem cells. In particular, provided herein are highly efficient and reproducible methods of obtaining human primitive macrophages and microglia from human pluripotent stem cells, where the primitive macrophages and microglia can be suitable for clinically relevant therapeutic applications.

Derivation of human microglia from pluripotent stem cells

Methods of using a small molecule MYH11 agonist to inhibit intimal hyperplasia and to maintain a contractile phenotype in vitro and in vivo are described. Also described herein are methods for generating human contractile smooth muscle cells from human pluripotent stem cells under defined conditions in the presence of the small molecule MYH11 agonist.

Human pluripotent stem cell-based screening for smooth muscle cell differentiation and disease

Provided are lyophilized formulations comprising pegylated arginine deiminase (ADI-PEG) and related reconstituted liquid compositions and methods of using the compositions for arginine depletion therapies, including for the treatment of various cancers.

Formulations of pegylated arginine deiminase

Provided are conjugates of an arginine deiminase (ADI) and a Tumor Necrosis Factor (TNF) superfamily ligand, and related compositions and methods of use thereof. Also provided are conjugates of a hexameric polypeptide and a trimeric polypeptide, conjugates of a first and second trimeric polypeptide, and related compositions and methods of use thereof.

Protein conjugates

The present invention relates to methods for reprogramming a somatic cell to pluripotency by administering into the somatic cell at least one or a plurality of potency-determining factors. The invention also relates to pluripotent cell populations obtained using a reprogramming method.

Reprogramming somatic cells into pluripotent cells using a vector encoding Oct4 and Sox2

Methods for generating human arterial endothelial cells under defined conditions in the absence of insulin are described. In particular, provided herein are efficient, defined, and scalable methods for generating human arterial endothelial cells from human pluripotent stem cells. Also provided herein are uses of human arterial endothelial cells obtained according to these methods. For example, methods of treating peripheral arterial disease and methods of screening agents for that effect adhesion of leukocytes to arterial endothelial cells are also provided.

Generating arterial endothelial cell populations

Methods for derivation, culture, and maturation of small hepatic progenitor cells are described.

Expansion and maintenance of adult primary human hepatocytes in culture

Provided herein are human arterial endothelial cell-seeded polymeric vascular grafts suitable for replacing or bypassing natural blood vessels and exhibiting increased long term patency rates and reduced leukocyte adhesion relative to grafts comprising venous endothelial cells. Methods for generating the human arterial endothelial cell-seeded vascular grafts and therapeutic uses of the same are also described.

Generating arterial endothelial cell-seeded vascular grafts

The present invention relates generally to isolated to arginine deiminase (ADI) proteins that have reduced cross-reactivity with anti-ADI-PEG 20 antibodies as compared to ADI-PEG 20 (pegylated ADI derived from), but which can have functional characteristics comparable to or better than ADI-PEG 20, compositions comprising the ADI proteins, and related methods of treating arginine-dependent diseases or related diseases such as cancer.

Arginine deiminase with reduced cross-reactivity toward ADI - PEG 20 antibodies for cancer treatment

The present invention relates to chemically defined and xenogeneic material-free methods for deriving endothelial cells from human pluripotent stem cells. In particular, the present invention provides highly efficient and reproducible methods of obtaining human endothelial cells from human pluripotent stem cells, where endothelial cells derived from the methods provided herein are suitable for clinically relevant therapeutic applications.

Human pluripotent stem cell-based system for generating endothelial cells

This disclosure relates generally to new methods of maintaining the expression of hepatic genes in human hepatocytes and method for maintaining the functional hepatic enzyme activity of primary hepatocytes in culture. The disclosure also encompasses new methods of deriving a population of pure hepatocytes without selecting or sorting the cells from the cultured pluripotent cells.

Generation of uniform hepatocytes from human embryonic stem cells by inhibiting TGF-beta and methods of maintaining hepatic cultures

The present invention relates to three-dimensional (3D) tissue constructs and methods of using such 3D tissue constructs to screen for neurotoxic agents. In particular, provided herein are methods of producing and using complex, highly uniform human tissue models comprising physiologically relevant human cells, where the tissue models have the degree of sample uniformity and reproducibility required for use in quantitative high-throughput screening applications.

Human pluripotent stem cell-based models for predictive developmental neural toxicity

Methods and compositions of erythroid cells that produce adult &#x3b2;-hemoglobin, generated by culturing CD31+, CD31+/CD34+ or CD34+ cells from embryonic stem cells under serum-free culture conditions.

Erythroid cells producing adult-type beta-hemoglobin generated from human embryonic stem cells

Growing community of inventors

Madison, WI, United States of America

James A Thomson